Israel-Medical-Healthcare

[genisi]

[One more indication for the inhaled version of AAT]

Kamada to begin Phase II AAT trial

http://globes-online.com/serveen/globes/docview.asp?did=1000307960&fid=942

There are more than 100,000 cases of bronchiectasis every year in the US alone.
Efrat Perez-Harpaz 10 Feb 08 13:02

Biopharmaceutical company Kamada Ltd. (TASE: KMDA) will begin Phase II clinical trials of the aerosolized version of its flagship product, Alpha-1 Antitrypsin (AAT), to treat bronchiectasis, which causes localized, irreversible dilatation of part of the bronchial tree. The company obtained European Medicines Agency (EMEA) approval for the trial last year.

Researchers report that there are more than 100,000 cases of bronchiectasis every year in the US alone. Inhaleable AAT is intended to reduce the inflammation in the lungs to prevent deterioration in their functioning.

Kamada said that in view of clinical reports from around the world suggest that AAT is also effective in treating other bronchial diseases, the company was considering developing the drug for these purposes.

In late January, Kamada raised a loan of $20 million from US venture lending fund Hercules Technology Growth Capital Inc. (Nasdaq: HTGC).